Drug profile

The FDA adverse-event record for Esafoxolaner,Eprinomectin,Praziquantel

17 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Esafoxolaner,Eprinomectin,Praziquantel. See the species affected, top reactions, and outcomes below.

17
adverse-event reports
5.9%
death-coded share
Cat
most-reported species
4
Ketosis - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
17
Total Reports
1
Deaths Reported
5.9%
Death Rate

Active Ingredients

Esafoxolaner,Eprinomectin,Praziquantel

Administration Routes

TopicalUnknownOralParenteral

Species Affected

Cat 14
Dog 3

Most Affected Breeds

Domestic Shorthair 8
Cat (unknown) 2
Domestic Longhair 2
Brittany 1
Retriever - Golden 1
Shih Tzu 1
Crossbred Feline/cat 1
Abyssinian cat 1

Most Reported Reactions

Ketosis 4
Lack of efficacy - NOS 3
Weight loss 3
Other abnormal test result NOS 3
Anorexia 2
Lack of efficacy (endoparasite) - heartworm 2
Not eating 2
Epiphora 2
Lack of efficacy (endoparasite) - tapeworm 2
Dilated pupils 2
Lack of efficacy (bacteria) - Borrelia 1
Hyperglycaemia 1

Outcome Breakdown

Ongoing
8 (47.1%)
Outcome Unknown
5 (29.4%)
Recovered/Normal
3 (17.6%)
Euthanized
1 (5.9%)

Esafoxolaner,Eprinomectin,Praziquantel Adverse Event Insights

17 reports name Esafoxolaner,Eprinomectin,Praziquantel; 1 recorded a death outcome (5.9% of reported events, not a population-level mortality rate). Active ingredient: Esafoxolaner,Eprinomectin,Praziquantel. Administration routes: Topical, Unknown, Oral, Parenteral.

By species: Cat (14 reports), Dog (3 reports). By breed: Domestic Shorthair (8), Cat (unknown) (2), Domestic Longhair (2).

Leading clinical signs: Ketosis (4), Lack of efficacy - NOS (3), Weight loss (3), Other abnormal test result NOS (3). Outcome, 17 coded reports: Ongoing leads at 47.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.